Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of Daratumumab for Reduction of Circulating Antibodies in Patients With High Allosensitization Awaiting Heart Transplantation

NCT04088903 is registered in ClinicalTrials.gov with Ronald Witteles as lead sponsor.

NCT NCT04088903
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04088903 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of Daratumumab for Reduction of Circulating Antibodies in Patients With High Allosensitization Awaiting Heart Transplantation
Lead sponsor
Ronald Witteles
Phase
Phase 1
Overall status
Withdrawn
Start date
April 1, 2021
Completion date
April 1, 2023
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

allosensitization, heart transplant failure and rejection